Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.31.1 (
micrococcal nuclease
)
2,818
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
hMeCP2 (human methylated DNA-binding protein 2), mutations of which cause most cases of
Rett syndrome
(
RTT
), is involved in the transmission of repressive epigenetic signals encoded by DNA methylation. The present work focuses on the modifications of chromatin architecture induced by
MeCP2
and the effects of
RTT
-causing mutants. hMeCP2 binds to nucleosomes close to the linker DNA entry-exit site and protects approximately 11 bp of linker DNA from
micrococcal nuclease
.
MeCP2
mutants differ in this property; the R106W mutant gives very little extra protection beyond the approximately 146-bp nucleosome core, whereas the large C-terminal truncation R294X reveals wild type behavior. Gel mobility assays show that linker DNA is essential for proper
MeCP2
binding to nucleosomes, and electron microscopy visualization shows that the protein induces distinct conformational changes in the linker DNA. When bound to nucleosomes,
MeCP2
is in close proximity to histone H3, which exits the nucleosome core close to the proposed
MeCP2
-binding site. These findings firmly establish nucleosomal linker DNA as a crucial binding partner of
MeCP2
and show that different
RTT
-causing mutations of
MeCP2
are correspondingly defective in different aspects of the interactions that alter chromatin architecture.
...
PMID:MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. 1766 Feb 93